RxDoctor Payments Data

Hyang Eun Sohn, MD

Internal Medicine · Los Angeles, CANPI 1477745222

Payments from drug & device makers

$4,494in general payments, 2019–2025

Across 207 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$711
  • GSK$639
  • Lilly USA, LLC$431
  • Novo Nordisk$387
  • Boehringer Ingelheim$365
  • Amgen$339
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,43899%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,494 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$83,945
Medicare patients
137
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin283$235,186
JanuviaSitagliptin Phosphate159$133,940
JanumetSitagliptin Phos/Metformin Hcl162$119,300
CreonLipase/Protease/Amylase86$85,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$65,775
TradjentaLinagliptin66$44,287
ProliaDenosumab25$41,471
VascepaIcosapent Ethyl102$40,912
OzempicSemaglutide42$40,296
FarxigaDapagliflozin Propanediol56$39,450
EliquisApixaban44$36,324
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr61$28,335
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$27,200
XareltoRivaroxaban36$22,900
LinzessLinaclotide36$20,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$365$290,676371 claims
MerckJanuvia, Janumet$77$253,239321 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$639$115,524208 claims
AbbVieCreon, Linzess, Restasis$237$115,059135 claims
AstraZenecaFarxiga, Breztri Aerosphere$711$66,65083 claims
AmgenProlia$339$41,47125 claims
Novo NordiskOzempic$387$40,29642 claims
PfizerEliquis$325$36,32444 claims
Johnson & JohnsonXarelto$44$22,90036 claims
Aimmune Therapeutics, Inc.Zenpep$28$9,45611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →